{
 "topic": "Polycystic Ovary Syndrome",
 "slug": "polycystic-ovary-syndrome",
 "category_id": 15298,
 "summary": "The most common endocrine disorder of reproductive-age women, presenting in adolescence with irregular cycles and hyperandrogenism, and why its diagnostic criteria and ultrasound findings differ for teens versus adults.",
 "written_by": "claude-sonnet",
 "references": [
  {
   "title": "Signs and Symptoms in Pediatrics",
   "author": "Henry M. Adam,Jane Meschan Foy",
   "pages": [
    555
   ]
  },
  {
   "title": "Update in Pediatrics",
   "author": null,
   "pages": [
    55
   ]
  },
  {
   "title": "The Clinician's Guide to Pediatric Nutrition",
   "author": "Natalie D. Muth;Mary Tanaka;",
   "pages": [
    356
   ]
  },
  {
   "title": "Algorithms in Pediatrics",
   "author": null,
   "pages": [
    112,
    113,
    118
   ]
  },
  {
   "title": "Kliegman R. Nelson Textbook of Pediatrics 2-Volume Set 22ed 2024",
   "author": null,
   "pages": [
    3369
   ]
  },
  {
   "title": "The Harriet Lane Handbook (The Johns Hopkins Hospital)",
   "author": null,
   "pages": [
    347
   ]
  },
  {
   "title": "The Harriet Lane Handbook 22nd Edition (2020) (The Johns Hopkins Hospital)",
   "author": null,
   "pages": [
    347
   ]
  },
  {
   "title": "Cover",
   "author": "Vitalsource Download",
   "pages": [
    1192
   ]
  }
 ],
 "short": [
  {
   "title": "In short",
   "content": "- Polycystic ovary syndrome (PCOS), first described by Stein and Leventhal in 1935, is the most common endocrine disorder in reproductive-age women, affecting about 5-15% of this population (roughly 10% of adolescent females), and frequently first presents during adolescence.\n- Core diagnostic pillars: menstrual irregularity as evidence of chronic anovulation, plus clinical or biochemical hyperandrogenism. Polycystic ovaries on ultrasound can support the diagnosis but their absence does not rule it out, and \u2014 critically \u2014 the adult ultrasound criterion does NOT apply to adolescents, since normal adolescent ovaries can appear \"polycystic\" simply from early anovulatory cycles in puberty.\n- Suggested adolescent-specific diagnostic approach (Witchel et al. 2019) requires being at least 2 years post-menarche; abnormal cycle criteria for adolescents include cycles under 21 or over 45 days in years 1-3 post-menarche, or under 21/over 35 days or fewer than 8 cycles/year beyond 3 years post-menarche, or any cycle over 90 days.\n- Hyperandrogenism presents clinically as hirsutism (male-pattern coarse hair growth), moderate-to-severe acne (an adolescent female with this degree of acne should be investigated for PCOS), or male-pattern alopecia; biochemically as elevated total/free testosterone, DHEA-S, or androstenedione. True virilization (clitoromegaly, voice deepening, rapidly progressive hirsutism) is NOT a feature of PCOS and instead suggests more severe hyperandrogenism from another cause.\n- The Rotterdam criteria (2 of 3: oligomenorrhea, hyperandrogenism, polycystic ovarian morphology on ultrasound \u2014 \u226520 follicles in one ovary and/or ovarian volume >10 mm3) are the most widely accepted adult approach; the Androgen Excess Society/NIH criteria instead require hyperandrogenism to be present.\n- PCOS is strongly associated with obesity, insulin resistance, and increased type 2 diabetes risk; other associations include dyslipidemia, cardiovascular disease, obstructive sleep apnea, and a high rate of depression, anxiety, and disordered eating.\n- Chronic anovulation with unopposed estrogen exposure raises endometrial cancer risk \u2014 patients should aim for at least 4 periods per year unless using contraception.\n- Before diagnosing PCOS in an adolescent with irregular cycles beyond 2 years post-menarche, other causes of irregular cycles (thyroid dysfunction, hyperprolactinemia) must be excluded, and this workup should occur before starting oral contraceptives for the irregular cycles.\n- Management is individualized: lifestyle changes are central, since even 5-10% weight loss meaningfully improves symptom control, and a BMI over 30 limits fertility; adolescents who are overweight/obese should be screened for lipid abnormalities, glucose intolerance/type 2 diabetes, obstructive sleep apnea, and depression/anxiety."
  }
 ],
 "long": [
  {
   "title": "Definition",
   "content": "Polycystic ovary syndrome (PCOS) is a common disorder of reproductive hormone function characterized by ovulatory dysfunction and hyperandrogenism. Ovulatory dysfunction manifests as clinical menstrual cycle irregularity and/or polycystic ovarian morphology on imaging; hyperandrogenism is either clinical (hirsutism, inflammatory acne, androgenic alopecia) or biochemical (elevated serum testosterone and/or DHEA-S), arising from ovarian thecal cell proliferation and excess androgen production."
  },
  {
   "title": "Epidemiology",
   "content": "PCOS is the most common endocrine disorder affecting adolescent females and reproductive-age women, with prevalence estimates of 5-15% depending on the diagnostic criteria used (about 6-15% in adults, roughly 10% of adolescents, higher with a positive family history). It is a leading cause of female infertility. The disorder typically emerges in adolescence, when a normal menstrual pattern fails to become established and clinical evidence of androgen excess is present."
  },
  {
   "title": "Etiology",
   "content": "The etiology of PCOS is multifactorial and not fully elucidated, involving a complex interplay of genetic factors, insulin resistance, and environmental factors leading to hyperinsulinemia and increased circulating androgens. Peripheral insulin resistance (which may or may not manifest as elevated serum insulin) and an increased LH-to-FSH ratio are hypothesized contributors, though an elevated LH:FSH ratio is common but not required for diagnosis. PCOS is strongly associated with obesity and excess adiposity, though it also occurs in normal-weight individuals."
  },
  {
   "title": "Diagnostics",
   "content": "The most widely accepted adult diagnostic approach is the Rotterdam criteria, requiring 2 of 3 features: oligomenorrhea, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound (20 or more follicles in one ovary and/or ovarian volume over 10 mm3). Alternative adult criteria (Androgen Excess Society, NIH) place greater emphasis on requiring hyperandrogenism specifically. Critically, the ultrasound/polycystic-morphology criterion used in adults does not apply to adolescents, because normal adolescent ovaries can appear polycystic simply from early anovulatory cycles during puberty; the appearance of multiple ovarian cysts is a diagnostic criterion for adults but not for teens. Suggested adolescent-specific criteria require being at least 2 years post-menarche, plus both hyperandrogenism (clinical or biochemical \u2014 elevated DHEA-S, free or total testosterone) and menstrual abnormality (amenorrhea or oligomenorrhea reflecting chronic anovulation). Abnormal cycle length in adolescents is defined as under 21 or over 45 days in the first 1-3 years post-menarche, or under 21/over 35 days or fewer than 8 cycles per year beyond 3 years post-menarche, or any single cycle lasting over 90 days. Laboratory evaluation for hyperandrogenemia includes total and free testosterone, DHEA-S, and androstenedione; other causes of irregular cycles, such as thyroid dysfunction or hyperprolactinemia, must be excluded before attributing symptoms to PCOS. Polycystic ovaries can support the diagnosis but their absence does not rule out PCOS, and conversely, not all patients with ovarian cysts have PCOS."
  },
  {
   "title": "Clinical features",
   "content": "Hyperandrogenism presents clinically as hirsutism (coarse hair growth in a male pattern \u2014 upper lip, chin, chest, upper abdomen, back), acne (an adolescent female with moderate-to-severe acne should be evaluated for PCOS, since pubertal acne is otherwise twice as prevalent and more often severe in adolescent males), and male-pattern alopecia. True virilization \u2014 clitoromegaly, voice deepening, increased musculature, or rapidly progressive hirsutism/alopecia \u2014 is not a feature of PCOS and instead suggests a more severe hyperandrogenic condition requiring separate evaluation. Chronic anovulation can produce oligomenorrhea, amenorrhea, dysfunctional uterine bleeding, or infertility, though about 20% of patients with PCOS have normal menstrual cycles; menstrual abnormalities are often long-standing, dating back to menarche, though primary amenorrhea from PCOS is rare (PCOS more typically causes eugonadotropic secondary amenorrhea, though it can occasionally cause primary amenorrhea). Additional associated clinical features include obesity and acanthosis nigricans."
  },
  {
   "title": "Complications",
   "content": "Adolescents with PCOS are at increased risk for obesity-related morbidities, including type 2 diabetes, cardiovascular disease and dyslipidemia, obstructive sleep apnea, low self-esteem, depression, and anxiety, as well as later adult reproductive health problems including infertility and endometrial cancer. Chronic anovulation with unopposed estrogen exposure specifically increases endometrial cancer risk. There is a high association between PCOS and depression, anxiety, and disordered eating."
  },
  {
   "title": "Treatment",
   "content": "Management should be individually tailored to each patient's symptoms and clinical features; there is no single diagnostic test, and likewise no single treatment approach. Lifestyle changes play a central role: preventing weight gain and addressing weight loss when BMI exceeds 30 (which limits fertility) is important, and even about 5-10% weight loss meaningfully improves symptom control. To reduce endometrial cancer risk from prolonged amenorrhea, patients not on contraception should aim for at least 4 periods per year. Obese adolescents with PCOS should be screened for lipid abnormalities, glucose intolerance or type 2 diabetes, obstructive sleep apnea, and depression/anxiety as part of comprehensive management. Hormonal treatment can be used when the underlying pathology involves the hypothalamic-pituitary-ovarian axis, as in PCOS."
  }
 ],
 "clinical": [
  {
   "title": "Diagnosing PCOS in the adolescent",
   "content": "In an adolescent at least 2 years post-menarche with irregular cycles (under 21 or over 45 days in years 1-3 post-menarche, or under 21/over 35 days or fewer than 8 cycles/year beyond that, or any cycle over 90 days), evaluate for both hyperandrogenism (clinical: hirsutism, moderate-to-severe acne, male-pattern alopecia; biochemical: elevated free/total testosterone, DHEA-S, androstenedione) and exclude other causes of irregular cycles (thyroid dysfunction, hyperprolactinemia) before diagnosing PCOS \u2014 do this evaluation before starting oral contraceptives for the irregular cycles, since starting hormonal therapy first can mask the underlying picture. Do not rely on pelvic ultrasound in this age group: polycystic-appearing ovaries are a normal finding in many adolescents from ongoing pubertal anovulatory cycles, so the adult ultrasound criterion should not be applied. Watch specifically for true virilization (clitoromegaly, voice change, rapidly progressive hirsutism) \u2014 this is not consistent with PCOS and should prompt evaluation for a more severe androgen-excess condition instead."
  },
  {
   "title": "Managing the adolescent with PCOS",
   "content": "Once PCOS is diagnosed, screen for its common comorbidities, especially in an overweight or obese adolescent: lipid panel, glucose tolerance/HbA1c for type 2 diabetes risk, evaluation for obstructive sleep apnea, and screening for depression and anxiety. Emphasize lifestyle intervention as first-line management \u2014 even a 5-10% weight loss can meaningfully improve symptoms \u2014 and counsel that a BMI over 30 limits fertility, so weight management also serves reproductive goals. For endometrial protection, ensure at least 4 menstrual periods per year unless the patient is on contraception, given the endometrial cancer risk from chronic anovulation and unopposed estrogen. Individualize further treatment (hormonal therapy, antiandrogens, metformin) based on the patient's predominant symptoms \u2014 menstrual irregularity, hyperandrogenism, or metabolic features \u2014 rather than a one-size-fits-all regimen."
  }
 ]
}